Multiple intracellular mRNA and protein pathway targets

The term "multiple intracellular mRNA and protein pathway targets" refers to a non-specific pharmacological designation used when a drug's therapeutic effect is mediated through a broad array of molecular interactions rather than a single defined receptor or enzyme. This classification is most prominently associated with Defibrotide, a polydisperse mixture of oligonucleotide salts used to treat hepatic veno-occlusive disease (FDA, 2016). The mechanism involves the modulation of various messenger RNA (mRNA) expressions and protein signaling pathways that regulate endothelial cell activation and stabilize the microvasculature (EMA, 2013). Specifically, these interactions lead to an increase in prostaglandin I2 and E2, a decrease in endothelin-1, and an enhancement of fibrinolytic activity by increasing tissue plasminogen activator expression (DrugBank, DB09207). Because the drug interacts with numerous intracellular components simultaneously, the exact molecular stoichiometry is complex and not fully elucidated (Pescador et al., 2013). Consequently, this term serves as a collective placeholder in clinical literature to describe polypharmacological activity that protects vascular integrity and reduces inflammatory damage.

Other names

Multi-target intracellular pathwaysEndothelial protective targetsIntracellular signaling networks

Modulation of mRNA expression and protein signaling to reduce endothelial activation and promote fibrinolysis.